Modern Clinical Trials: ADmirable and DISCOVER Data Insights for a Diverse Patient Population

EP: 1.Understanding Atopic Dermatitis as an Immune-Mediated Disease

EP: 2.Bridging the Gaps: Health Care Professional Knowledge Gaps in AD Pathophysiology

EP: 3.Beyond the Itch: The Full Spectrum of AD Symptoms and Their Impact on Patients

EP: 4.Recognizing AD Across All Skin Tones

EP: 5.Diagnostic Challenges and Patient Education Across Skin Tones

EP: 6.Biologic Therapy Decision-Making and Monitoring in AD

EP: 7.Access, Adaptation, and Cost-Effectiveness in AD Treatment

EP: 8.Empowering Health Care Professionals: Training and Resources for Diverse AD Care

EP: 9.Atopic Dermatitis Clinical Trial Representation: Addressing Historical Gaps

Now Viewing

EP: 10.Modern Clinical Trials: ADmirable and DISCOVER Data Insights for a Diverse Patient Population

EP: 11.From Research to Practice: Translating AD Clinical Trial Results and Overcoming Barriers

EP: 12.Improving Access and Care for All Patients With Atopic Dermatitis

Content above is prompted by the following:

The ADmirable trial represents a landmark phase 3B study of lebrikizumab (an IL-13 inhibitor) specifically designed to include patients with Fitzpatrick skin types IV to VI, encompassing adolescents and adults with moderate to severe atopic dermatitis and more pigmented skin. This open-label study followed patients over 16 weeks and demonstrated that nearly 70% achieved at least 75% improvement (EASI-75) compared with baseline across different skin types. Importantly, subgroup analyses confirmed efficacy across different racial groups, providing crucial evidence for treatment effectiveness in traditionally underrepresented populations.

The DISCOVER study, a phase 4 investigation of dupilumab in adolescents and adults with skin of color, extended follow-up to 24 weeks and included more than 80% African American participants. Results showed that more than 70% of patients achieved EASI-75 response, with consistent efficacy demonstrated across the diverse study population. Both trials revealed safety profiles in patients with skin of color that were comparable to those observed in the original pivotal phase 3 studies, providing reassurance about treatment safety across different populations.

These studies represent a paradigm shift in atopic dermatitis research by intentionally enrolling patients with darker skin tones and generating population-specific efficacy and safety data. The trials evaluated not only traditional end points but also addressed concerns specific to patients with skin of color, such as postinflammatory pigmentation changes using specialized assessment tools. This comprehensive approach provides clinicians with evidence-based confidence when recommending these therapies to their diverse patient populations and addresses the historical gap in representative clinical trial data.